Contrast-associated acute kidney injury (CA-AKI) is the broad term for a sudden decline in renal function within 48 hours after IV administration of radiocontrast, whether or not the contrast caused it. Contrast-induced acute kidney injury (CI-AKI) refers to the subset of CA-AKI that is thought to be directly caused by contrast material. Diagnosis of CI-AKI is based on a progressive rise in serum creatinine 24 to 48 hours, usually asymptomatic, after contrast is given in patients without other causes of AKI. Treatment is supportive. Volume loading with isotonic saline before and after contrast administration may help in prevention.
Contrast-induced AKI is acute tubular necrosis caused by an iodinated radiocontrast agent, all of which are potentially nephrotoxic. However, risk is mitigated with nonionic low-osmolar contrast media (compared with ionic, higher osmolar agents used in the past) (1). While high-osmolar agents have an osmolality of approximately 1400 to 1800 mOsm/kg (or mmol/kg), second-generation low-osmolar agents (eg, iohexol, iopamidol, ioxaglate) have an osmolality of approximately 500 to 850 mOsm/kg (or mmol/kg), which is still higher than blood osmolality. Iodixanol is an iso-osmolar agent with an osmolality of 290 mOsm/kg (or mmol/kg), about equal to that of blood.
The precise mechanism of radiocontrast toxicity is unknown but is suspected to be some combination of renal vasoconstriction and direct cytotoxic effects, perhaps through formation of reactive oxygen species, causing acute tubular necrosis.
Most patients have no symptoms. When present, symptoms are those of acute kidney injury in general. Renal function usually later returns to normal.
Risk factors for contrast-induced acute kidney injury
Risk factors for nephrotoxicity are the following (2, 3, 4, 5, 6, 7):
Older age (> 65 to 75 years)
Preexisting chronic kidney disease
High doses (eg, > 100 mL) of a contrast agent (eg, during percutaneous coronary interventions)
Factors that reduce renal perfusion, such as volume depletion or the concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, and possibly angiotensin-converting enzyme (ACE) inhibitors
Concurrent use of nephrotoxic medications (eg, aminoglycosides)
General references
1. Susantitaphong P, Eiam-Ong S. Nonpharmacological strategies to prevent contrast-induced acute kidney injury. Biomed Res Int. 2014;2014:463608. doi:10.1155/2014/463608
2. American College of Radiology Committee on Drugs and Contrast Media of the ACR Commission on Quality and Safety. ACR Manual on Contrast Media. 2026. Accessed July 8, 2026.
3. Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int. 2014;2014:741018. doi:10.1155/2014/741018
4. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155. doi:10.1056/NEJMra1805256
5. Mehran R, Owen R, Chiarito M, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021;398(10315):1974-1983. doi:10.1016/S0140-6736(21)02326-6
6. Moos SI, van Vemde DN, Stoker J, Bipat S. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol. 2013;82(9):e387-e399. doi:10.1016/j.ejrad.2013.04.029
7. Xu T, Lin M, Shen X, et al. Association of the classification and severity of heart failure with the incidence of contrast-induced acute kidney injury. Sci Rep. 2021;11(1):15348. Published 2021 Jul 28. doi:10.1038/s41598-021-94910-1
Diagnosis of Contrast-Induced AKI
Serum creatinine
Urinalysis
Screening with pre- and post-procedure kidney function testing is usually performed in patients with pre-existing kidney disease, older age, high contrast load, or other risk factors.
Serum creatinine often increases within 24 to 48 hours after a contrast study. Microscopic analysis of a urine sample often reveals muddy brown casts or renal tubular epithelial cells.
After femoral artery catheterization, contrast nephropathy may be difficult to distinguish from renal atheroembolism. Factors that can suggest renal atheroemboli include the following:
Delay in onset of increased creatinine > 48 hours after the procedure
Presence of other atheroembolic findings (eg, livedo reticularis of the lower extremities or bluish discoloration of the toes)
Persistently poor renal function that may deteriorate in a stepwise fashion
Transient eosinophilia or eosinophiluria and low C3 complement levels (1) (measured if atheroemboli are seriously considered)
Diagnosis reference
1. Scolari F, Ravani P. Atheroembolic renal disease. Lancet. 2010;375(9726):1650-1660. doi:10.1016/S0140-6736(09)62073-0
Treatment of Contrast-Induced AKI
Supportive care
Treatment is supportive, including fluid administration, withdrawal of other nephrotoxic agents, monitoring, and rarely kidney replacement therapy (1).
Treatment reference
1. McCullough PA, Choi JP, Feghali GA, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016;68(13):1465-1473. doi:10.1016/j.jacc.2016.05.099
Prevention of Contrast-Induced AKI
Preventing contrast nephropathy involves avoiding contrast when possible (eg, not using CT to diagnose appendicitis) and, when contrast is necessary for patients with risk factors, using a nonionic agent with the lowest osmolality at a low dose.
When contrast is given, mild volume expansion with isotonic saline (ie, 154 mEq/L or mmol/L) is ideal; protocols include 1 to 1.5 mL/kg/hour given for 12 hours before and for 24 hours after contrast administration, or 100 mL/hour given for 6 to 12 hours before and for 4 to 12 hours after contrast administration (1). For patients with high risk of contrast-induced AKI in emergent or outpatient settings, an abbreviated course of fluids can be given (2). For example, 3 mL/kg of isotonic saline is given the hour before the procedure and 1 mL/kg of isotonic saline is given 4 to 6 hours after the procedure. A sodium bicarbonate (NaHCO3) solution may also be infused but has no proven advantage over normal saline (3). Acetylcysteine, an antioxidant, also has no proven benefit over normal saline. Volume expansion may be most helpful in patients with mild preexisting kidney disease and exposure to a low dose of contrast. Volume expansion should be avoided or used cautiously in heart failure. Nephrotoxic medications are avoided before and after the procedure.
Periprocedural dialysis has no proven benefit compared with other less invasive strategies in preventing acute kidney injury in patients who have chronic kidney disease and who require high doses of contrast (4). Patients undergoing regular hemodialysis for kidney failure who require contrast do not need supplementary, prophylactic hemodialysis after the procedure.
Prevention references
1. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155. doi:10.1056/NEJMra1805256
2. Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814-1823. doi:10.1016/S0140-6736(14)60689-9
3. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603-614. doi:10.1056/NEJMoa1710933
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
Key Points
Although most patients recover from use of iodinated radiocontrast without clinical consequences, all such radiocontrast is nephrotoxic.
Suspect contrast-induced AKI if serum creatinine increases 24 to 48 hours after a contrast study.
Decrease the risk of contrast-induced AKI, particularly in patients at risk, by minimizing the use and volume of low osmolar contrast and expanding volume when possible.
Drug Information for the Topic



